Expert opinion on thyroid complications in immunotherapy

This publication has 46 references indexed in Scilit:

• Immune-related adverse events with immune checkpoint blockade: a comprehensive review
  European Journal of Cancer, 2016
• Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
  The Lancet Oncology, 2015
• Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
  New England Journal of Medicine, 2015
• Induction of Painless Thyroiditis in Patients Receiving Programmed Death 1 Receptor Immunotherapy for Metastatic Malignancies
  The Journal of Clinical Endocrinology & Metabolism, 2015
• Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
  The Lancet Oncology, 2015
• Thyroid-Like Ophthalmopathy in a Euthyroid Patient Receiving Ipilimumab
  Orbit, 2014
• Ipilimumab-Induced Orbital Inflammation Resembling Graves Disease With Subsequent Development of Systemic Hyperthyroidism From CTLA-4 Receptor Suppression
  Ophthalmic Plastic & Reconstructive Surgery, 2014
• Clinical Practice Guidelines for Hypothyroidism in Adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association
  Thyroid®, 2012
• Thyroid Dysfunction from Antineoplastic Agents
  JNCI: Journal of the National Cancer Institute, 2011
• Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy
  European Journal of Endocrinology, 2011